Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'

DSpace Repository

Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'

Author: Bedikian, Agop Y.; Garbe, Claus; Conry, Robert; Lebbe, Celeste; Grob, Jean J.
Tübinger Autor(en):
Garbe, Claus
Published in: Melanoma Research (2014), Bd. 24, H. 3, S. 237-243
Verlagsangabe: Lippincott Williams & Wilkins
Language: English
Full text: http://dx.doi.org/10.1097/CMR.0000000000000056
ISSN: 0960-8931
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)